This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Langer, C. J. Articles by Mehta, M. P. Search for Related Content PubMed PubMed Citation Articles by Langer, C. J. Articles by Mehta, M. P.

Current Management of Brain Metastases, With a Focus on Systemic Options

From the Division of Thoracic Oncology, Fox Chase Cancer Center, Philadelphia, PA; and Department of Human Oncology, University of Wisconsin Medical School, Madison, WI

Address reprint requests to Corey J. Langer, MD, FACP, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111, e-mail: CJ_Langer{at}fccc.edu

Brain metastases are an important sequelae of many types of cancer, most commonly lung cancer. Current treatment options include whole-brain radiation therapy (WBRT), surgical resection, stereotactic radiosurgery, and chemotherapy. Corticosteroids and antiepileptic medications are commonly used for palliation of mass effect and seizures, respectively. The overall median survival is only 4 months after WBRT. Combined-modality strategies of WBRT with either chemotherapy or novel anticancer agents are under clinical investigation. Promising results have been obtained with several experimental agents and confirmatory phase III trials are underway. Although improvement in overall survival has not been seen universally, reduction in death due to progression of brain metastases and prolongation of the time to neurologic and neurocognitive progression have been reported in selected series. On the basis of these findings, it might be possible to identify new agents that may enhance the efficacy of WBRT.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

This article has been cited by other articles:

				C.-H. Gow, C.-R. Chien, Y.-L. Chang, Y.-H. Chiu, S.-H. Kuo, J.-Y. Shih, Y.-C. Chang, C.-J. Yu, C.-H. Yang, and P.-C. Yang Radiotherapy in Lung Adenocarcinoma with Brain Metastases: Effects of Activating Epidermal Growth Factor Receptor Mutations on Clinical Response Clin. Cancer Res., January 1, 2008; 14(1): 162 - 168. [Abstract] [Full Text] [PDF]

				P. A. Kvale, P. A. Selecky, and U. B. S. Prakash Palliative Care in Lung Cancer: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition) Chest, September 1, 2007; 132(3_suppl): 368S - 403S. [Abstract] [Full Text] [PDF]

				G. P. Kalemkerian Guidelines Are Never Enough: A Commentary on "When Guidelines Are Not Enough" J. Clin. Oncol., May 1, 2007; 25(13): 1810 - 1811. [Full Text] [PDF]

				R. R. Patel and M. P. Mehta Targeted Therapy for Brain Metastases: Improving the Therapeutic Ratio Clin. Cancer Res., March 15, 2007; 13(6): 1675 - 1683. [Abstract] [Full Text] [PDF]

				D. C. Gammon, M. S. Bhatt, L. Tran, A. Van Horn, M. Benvenuti, and M. J. Glantz Intrathecal topotecan in adult patients with neoplastic meningitis. Am. J. Health Syst. Pharm., November 1, 2006; 63(21): 2083 - 2086. [Abstract] [Full Text] [PDF]

				D Schadendorf, A Hauschild, S Ugurel, A Thoelke, F Egberts, M Kreissig, R Linse, U Trefzer, T Vogt, W Tilgen, et al. Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study. Ann. Onc., October 1, 2006; 17(10): 1592 - 1597. [Abstract] [Full Text] [PDF]

				M. A. Vogelbaum and J. H. Suh Resectable Brain Metastases J. Clin. Oncol., March 10, 2006; 24(8): 1289 - 1294. [Abstract] [Full Text] [PDF]

				D. Khuntia, P. Brown, J. Li, and M. P. Mehta Whole-Brain Radiotherapy in the Management of Brain Metastasis J. Clin. Oncol., March 10, 2006; 24(8): 1295 - 1304. [Abstract] [Full Text] [PDF]

				D. Pectasides, M. Pectasides, and T. Economopoulos Brain metastases from epithelial ovarian cancer: a review of the literature. Oncologist, March 1, 2006; 11(3): 252 - 260. [Abstract] [Full Text] [PDF]